comparemela.com

Latest Breaking News On - Founded entity - Page 19 : comparemela.com

PureTech Founded Entity Akili Secures $160 Million in Financing; Poised to Deliver on the Promise of Digital Therapeutics – Consumer Electronics Net

PureTech Founded Entity Akili Secures $160 Million in Financing; Poised to Deliver on the Promise of Digital Therapeutics – Consumer Electronics Net
consumerelectronicsnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from consumerelectronicsnet.com Daily Mail and Mail on Sunday newspapers.

PureTech Founded Entity Gelesis Appoints Procter & Gamble Veteran Jane Wildman to Board of Directors

Press release content from Business Wire. The AP news staff was not involved in its creation. PureTech Founded Entity Gelesis Appoints Procter & Gamble Veteran Jane Wildman to Board of Directors April 26, 2021 GMT PureTech Founded Entity, Gelesis, announced the appointment of marketing executive Jane Wildman to its Board of Directors. Ms. Wildman has extensive experience as a board member, president and chief marketing officer across Fortune-25, mid-sized and start-up companies. The appointment comes as Gelesis looks toward the broad United States launch of its commercial product, Plenity® this year. (Photo: Business Wire) PureTech Founded Entity, Gelesis, announced the appointment of marketing executive Jane Wildman to its Board of Directors. Ms. Wildman has extensive experience as a board member, president and chief marketing officer across Fortune-25, mid-sized and start-up companies. The appointment comes as Gelesis looks toward the broad United States launch of its commerci

PureTech Health : Founded Entity Gelesis Appoints Procter & Gamble Veteran Jane Wildman to Board of Directors

Message : Required fields Ms. Wildman brings extensive experience in brand building and marketing in the consumer health and wellness space, both at established market leaders and start-ups PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, is pleased to note that its Founded Entity, Gelesis, announced the appointment of marketing executive Jane Wildman to its Board of Directors. Ms. Wildman has extensive experience as a board member, president and chief marketing officer across Fortune-25, mid-sized and start-up companies. The appointment comes as Gelesis looks toward the broad United States launch of its commercial product, Plenity®, this year.

Investegate |PureTech Health PLC Announcements | PureTech Health PLC: Karuna Prices Approximately $250M Public Offering

Investegate |PureTech Health PLC Announcements | PureTech Health PLC: Karuna Prices Approximately $250M Public Offering
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.

PureTech Founded Entity Karuna Therapeutics Announces New England Journal of Medicine Publication of Data from EMERGENT-1 Phase 2 Trial Evaluating KarXT in Schizophrenia

Posted on 7565 PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, is pleased to note that its Founded Entity, Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, announced that results from the EMERGENT-1 Phase 2 clinical trial evaluating KarXT for the treatment of schizophrenia were published in the New England Journal of Medicine (NEJM). The published manuscript titled “Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia” is available online and appears in the February 25, 2021 issue of

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.